|

JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer

RECRUITINGPhase 2Sponsored by Hunan Province Tumor Hospital
Actively Recruiting
PhasePhase 2
SponsorHunan Province Tumor Hospital
Started2023-06-01
Est. completion2024-12-01
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04951947

Summary

This is a prospective, single-arm phase II clinical study to evaluate the efficacy and safety of JS-201 combined with lenvatinib in the treatment of small-cell lung cancer that has failed previous chemotherapy combined with PD-L1. The primary observational endpoint is ORR, and the secondary observational endpoint is PFS, OS. The intervention mode is JS201 300mg i.v Q2w, lenvatinib 8mg po. Qd.

Eligibility

Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

* 1\. The imaging diagnosis is the extensive stage of SCLC
* 2\. The patient failed first-line EC+PD-L1 treatment
* 3 PS 0-1

Exclusion Criteria:

* 1\. Diagnosed as non-small cell lung cancer
* 2\. Women during pregnancy
* 3\. Patients with symptomatic brain metastases
* 4\. PS≥2

Conditions3

CancerLung CancerSmall Cell Lung Cancer

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.